BCTX - BriaCell Therapeutics Corp.

4.01
-0.060   -1.496%

Share volume: 62,078
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$4.07
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
53%
Profitability 35%
Dept financing 38%
Liquidity 50%
Performance 75%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.25%
1 Month
-4.07%
3 Months
-68.05%
6 Months
-49.78%
1 Year
13.92%
2 Year
28.53%
Key data
Stock price
$4.01
P/E Ratio 
0.00
DAY RANGE
$3.97 - $4.14
EPS 
-$27.44
52 WEEK RANGE
$0.61 - $14.68
52 WEEK CHANGE
$13.60
MARKET CAP 
20.723 M
YIELD 
N/A
SHARES OUTSTANDING 
1.884 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-29-2025
NEXT EARNINGS DATE
06-13-2025
BETA 
1.98
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$197,928
AVERAGE 30 VOLUME 
$195,140
Company detail
CEO: William V. Williams
Region: US
Website: briacell.com
Employees: 8
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BriaCell Therapeutics Corp. engages in developing immunotherapies for the treatment of cancer. Lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors. Company also has a cooperative research and development agreement with the National Cancer Institute.

Recent news